Acute Respiratory Distress Syndrome (ARDS) Clinical Trials

Find Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Near You

Pulmonary Immune Cell-microbiome Interactions in Acute Respiratory Distress Syndrome: the ILLUMINA-1 Study

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

The overall aim is to compare the composition and spatial heterogeneity of the following in critically ill intensive care unit (ICU) patients: i) immune cell populations and their activation patterns, ii) the surrounding cytokine-chemokine milieu, including trans-compartmental fluxes of these mediators between the lung and bloodstream, and iii) the lung microbiome. Main hypotheses: * The immune cell population in bronchoalveolar lavage fluid (BALF) from patients with ARDS is dominated by neutrocytes, while T cells are depleted, and show evidence of hyper-activation and exhaustion * T cell hyper-activation and exhaustion is specifically compartmentalised to the lungs, and much more pronounced in moderate-to-severe than none-to-mild ARDS * Cyto- and chemokines derived from pulmonary immune cells are higher in moderate-to-severe than none-to-mild ARDS with a greater release from lungs to the bloodstream, notably of IL-6 and IL-8. * The differences in T cell profile in BALF, notably the ratio between regulatory T cells and T helper 17 cells, will change with disease severity over time, and can be explained by the presence of tI-IFN antibodies and/or a low microbial diversity of the respiratory tract with low enrichment from the oral cavity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Inclusion criteria - moderate-to-severe ARDS

• Admitted to the ICU at Hvidovre Hospital

• Intubated within the past 72 hours

• Moderate-to-severe ARDS according to the Berlin definition19

• Age ≥ 18 years

• Admitted to the ICU at Hvidovre Hospital

• Intubated within the past 72 hours

• None-to-mild ARDS according to the Berlin definition19

• Age ≥ 18 years

Locations
Other Locations
Denmark
Hvidovre Hospital, University of Copenhagen
RECRUITING
Hvidovre
Contact Information
Primary
MD, PhD, Ronni Plovsing
ronni.thermann.reitz.plovsing.01@regionh.dk
+45386220721
Backup
MD Katrine Schneider
katrine.schneider@regionh.dk
+4528118147
Time Frame
Start Date: 2023-03-14
Estimated Completion Date: 2028-11-30
Participants
Target number of participants: 40
Treatments
None-mild ARDS
Moderate-severe ARDS
Sponsors
Leads: Hvidovre University Hospital

This content was sourced from clinicaltrials.gov